Combination Antiangiogenic TKI/ICI Therapy in Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Combination Antiangiogenic Tyrosine Kinase Inhibition and Anti-PD1 Immunotherapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Safety, Tolerance, and Clinical Outcomes
Cancer Med 2021 Apr 01;10(7)2341-2349, AL Laccetti, B Garmezy, L Xiao, M Economides, A Venkatesan, J Gao, E Jonasch, P Corn, A Zurita-Saavedra, LC Brown, C Kao, EN Kinsey, RT Gupta, MR Harrison, AJ Armstrong, DJ George, N Tannir, P Msaouel, A Shah, T Zhang, MT CampbellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.